

FDA issues safety alert for COVID-19 risk with fecal transplant

26 March 2020



CoV-2; develop criteria for excluding donors and donor stool based on screening and testing; and obtain informed consent from patients regarding the potential for transmission of SARS-CoV-2 via FMT, including FMT prepared from the stool of donors who are asymptomatic for COVID-19.

The FDA requests that any adverse events or side effects related to the use of FMT be reported to the MedWatch Safety Information and Adverse Event Reporting Program.

More information: [More Information](#)

[Health News](#) Copyright © 2020 [HealthDay](#). All rights reserved.

(HealthDay)—The U.S. Food and Drug Administration issued a *MedWatch* Safety Alert on Tuesday about the potential risk for SARS-CoV-2 transmission with the use of fecal microbiota for transplantation (FMT) to treat *Clostridioides difficile* infection.

Recent data have shown that SARS-CoV-2 RNA and/or the SARS-CoV-2 virus is present in the stool of patients with the novel [coronavirus](#) (COVID-19), suggesting that SARS-CoV-2 could be transmitted by FMT. Testing of nasopharyngeal specimens from stool donors for SARS-CoV-2 is not widely available at this time, so information on the sensitivity of directly testing stool for SARS-CoV-2 is limited.

The FDA directed [health care workers](#) to implement the following protections for any FMT with stool donated after Dec. 1, 2019: conduct [donor](#) screening to identify donors who may be or recently could have been infected with SARS-CoV-2; [test](#) donors and/or donor stool for SARS-

APA citation: FDA issues safety alert for COVID-19 risk with fecal transplant (2020, March 26) retrieved 27 May 2022 from <https://medicalxpress.com/news/2020-03-fda-issues-safety-covid-fecal.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.